Ronan Kelly, MD

Ronan Kelly, MD

Articles by Ronan Kelly, MD

CheckMate 577: Adjuvant Nivolumab Plus Neoadjuvant Chemoradiotherapy for Esophageal and Gastroesophageal Cancer

Ronan Kelly, MDEsophageal Cancer | June 3, 2025

Dr. Kelly discusses the first overall survival results from CheckMate 577 and how they compare to previous DFS results.

LAG-3 and PD-1 Inhibitors for Esophageal and Gastroesophageal Junction Cancer: A Phase Ib Trial

Ronan Kelly, MDEsophageal Cancer | March 19, 2025

Dr. Ronan Kelly describes his trial on nivolumab with relatlimab for the treatment of resectable esophageal/GEJ cancer.